Genomics investments start to pay off

12/18/2012 | Xconomy

Investments in whole genome sequencing and analysis are starting to pay off, with new drugs, diagnostics and disease management strategies, Luke Timmerman writes. Two companies, Adaptive Biotechnologies and Sequenta, are pioneering new approaches to disease diagnosis and management through sequencing that would have been cost-prohibitive several years ago. Studies are under way to determine whether genomics technologies will lower health care costs and improve outcomes, but the personalized medicine payoff is imminent, Timmerman writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ